PT  - JOURNAL ARTICLE
AU  - G M Connolly
AU  - B G Gazzard
AU  - D A Hawkins
TI  - Fixed drug eruption due to foscarnet.
AID  - 10.1136/sti.66.2.97
DP  - 1990 Apr 01
TA  - Genitourinary Medicine
PG  - 97--98
VI  - 66
IP  - 2
4099  - http://sti.bmj.com/content/66/2/97.short
4100  - http://sti.bmj.com/content/66/2/97.full
SO  - Genitourin Med1990 Apr 01; 66
AB  - A case of fixed drug eruption (FDE) secondary to foscarnet is reported. This drug has recently become available on a compassionate use basis for treatment of cytomegalovirus (CMV) infection which may cause significant disease in immunosuppressed patients. Foscarnet provides a useful alternative to the only licensed anti-CMV drug currently available, namely ganciclovir (DHPG), as it has a different toxicity profile. In particular, it does not appear to cause bone marrow suppression which is of importance in AIDS patients as many of them are taking concurrent zidovudine.